The application for the 12th annual installment of Endocrine Society’s Type 1 Diabetes Fellows series is now available. Applicants will have until January 31, 2025 to apply and will receive notifications and more details by no later than mid-February. Fellows that are invited to attend the in-person meeting will receive a promotional code for complimentary registration to ENDO 2025, as well as a travel stipend.
As in years past, the Type 1 Diabetes Fellows Program will have three core components:
On-demand didactic sessions;
A prestigious, in-person meeting held in San Francisco, CA, July 10-11, 2025, ahead of ENDO, where fellows get the exclusive opportunity to meet with experts in T1D and product demonstrations with industry representatives;
A 30-minute podcast describing the latest standards in T1D management and lessons learned, featuring one of our invited fellows
Please note: Early Career Forum and the Type 1 Diabetes Fellows in-person program occur on the same day. If applying to both programs, please note that you can only participate in one.
Learning Objectives
Upon successful completion of these educational initiatives, participants should be better able to:
Discuss the prevalence and progression of type 1 diabetes to recognize signs and support early diagnosis.
Discuss prevalence of type 1 diabetes at each stage, and also prevalence of overweight or obesity in this population.
Devise individualized treatment strategies that use new and emerging insulin and non-insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, exercise prescription, and sick day and hypoglycemia management of individuals with type 1 diabetes.
Describe current and emerging therapy for the treatment of pre-clinical type 1 diabetes.
Past Program Highlights (2024):
Gain insights into the enriching experience participants had in our last year's workshop. Explore the agenda, topics covered, and the valuable takeaways from the June 2024 program. This will give you a glimpse of what to expect in our upcoming workshop in July 2025.
2024 Program Agenda
Thursday, May 30, 2024
6:00-6:30 PM
Welcome Reception
6:30-7:00 PM
Dinner
7:00-7:45 PM
Keynote Address: Innovations in Insulin Therapy Irl B. Hirsch, MD, University of Washington
7:45-8:00 PM
Q&A
8:00-9:00 PM
Product Showcase
Friday, May 31, 2024
7:00-8:00 AM
Registration and Breakfast with the Faculty
8:00-8:15 AM
Welcoming Remarks Rodolfo J. Galindo, MD, University of Miami
8:15-10:30 AM
Diabetes Technology
CGM Use and Interpretation with MDI
Viral Shah, MD, Indiana University School of Medicine
CGM Use and Interpretation with Open Loop Georgia Davis, MD, Emory University School of Medicine
CGM Use and Interpretation with Closed Loop Grazia Aleppo, MD, Northwestern University
10:30-11:00 AM
Break & Questions for Industry Representatives
11:00 AM-12:00 PM
Small Group Discussions
T1D and Technology in the Older Individual Medha Munsi, MD, Harvard Medical School
Sick Day Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes Amy Hess Fischl, MS RDN BC-ADM CDCES, University of Chicago
Type 1 Diabetes in Pregnancy: Before, During, and After Camille Powe, MD, Massachusetts General Hospital
In-Patient Management Guillermo E. Umpierrez, MD, CDCES, FACE, MACP,Emory University School of Medicine
Discussing Pump Therap Grazia Aleppo, MD, Northwestern University
Billing Carol Wysham, MD, Rockwood Clinic PS
12:00-1:00 PM
Lunch Discussion with Faculty
1:00-1:45 PM
Obesity and T1D Eden Miller, DO, Rocky Mountain Diabetes and Osteoporosis Center
1:45-2:30 PM
Novel Immune Therapy Desmond A. Schatz, MD, University of Florida College of Medicine
2:30-3:00 PM
Break & Questions for Industry Representatives
3:00-4:00 PM
Small Group Discussions
T1D and Technology in the Older Individual Medha Munsi, MD, Harvard Medical School
Sick Day Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes Amy Hess Fischl, MS RDN BC-ADM CDCES, University of Chicago
Type 1 Diabetes in Pregnancy: Before, During, and After Camille Powe, MD, Massachusetts General Hospital
In-Patient Management
Guillermo E. Umpierrez, MD, CDCES, FACE, MACP,Emory University School of Medicine
Discussing Pump Therapy Grazia Aleppo, MD, Northwestern University
Billing Carol Wysham, MD, Rockwood Clinic PS
4:00-4:45 PM
Fresh Look at Insulin Dr. Bernard Zinman, FRCP, FACP, MD, Mount Sinai Hosp, University of Toronto
4:45-5:00 PM
Closing Comments Rodolfo J. Galindo, MD,University of Miami
T1D in Underserved Populations: Lorena Wright, MD, University of Washington School of Medicine
The Pathogenesis of T1D: The Future for Preserving Beta Cell Function: Mark Atkinson, PhD, University of Florida
Applying New Billing Rules to Outpatient Diabetes Care: Carol Wysham, MD, Rockwood Clinic PS
Stages of Diabetes: Carla J. Greenbaum, MD, Benaroya Research Institute
Preparing for Future Careers in Endocrinology: What I Wish I was Told When I Left my Fellowship: Luisa Duran, MD, John Muir Health
Newly Diagnosed of Type 1 Diabetes: Irl B. Hirsch, MD, University of Washington
Hypoglycemia in T1D: Risks and Practical Prevention Strategies: Elizabeth Seaquist, MD, University of Minnesota
T1D and the Prevention and Treatment of Macrovascular Disease: Robert H. Eckel, MD, University of Colorado
The Endocrinologist’s Role in Screening and Managing Microvascular Disease: Janet McGill, MD, MA, FACE, Washington University in St. Louis
Identifying and Confronting Challenging Transitions: Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
Developmental Considerations for Youth with T1D and Their Families: Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
Type 1 Diabetes in Pregnancy: Before, During, and After: Camille Powe, MD, Massachusetts General Hospital
Adjunctive Therapies for T1D: Anne Peters, MD, USC Westside Center for Diabetes
Visa Information
All individuals traveling from outside the United States must apply for entry visas as soon as possible and at least four months prior to the date of travel for ENDO 2025. The most updated information may be found at the US State Department site. Scientists visiting the U.S. may find helpful information at The National Academies of Sciences website. Visa appointment wait times can be found here.
Please do not wait until ENDO 2025 registration opens in February 2025 before applying for a visa. All visitors traveling to the U.S. from visa waiver countries (i.e., Europe, Japan, Australia, etc.) must meet all requirements. If you need more information on the Electronic System for Travel Authorization (ESTA) or a list of visa waiver countries, click here.
To request a visa invitation letter or learn more, visit the Visa Information page.
